Regulatory Focus™ > News Articles > 2019 > 8 > MHRA to Land a New Interim Chief Executive Ahead of Brexit

Regulatory NewsRegulatory News
Posted 20 August 2019 | By Zachary Brennan 

MHRA to Land a New Interim Chief Executive Ahead of Brexit

Beginning 20 September, June Raine will be the new interim Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA).

Raine will replace Ian Hudson, who will step down after 18 years with MHRA, including six years as chief executive. In addition to Hudson, John Wilkinson, director of devices at MHRA, will step down at the end of October. In June, Wilkinson discussed with Focus several initiatives that MHRA is working on, including how to deal with Brexit.

While working at MHRA’s predecessor Medicines Division since 1985 and at MHRA since 2003, Raine has served as MHRA’s director of the Vigilance and Risk Management of Medicines (VRMM) division since 2006. Her experience also includes chairing the European Pharmacovigilance Risk Assessment Committee (PRAC) on behalf of the European Medicines Agency from 2012 to 2018.

Sir Michael Rawlins, chairman of MHRA, said in a statement: “Raine has spent her professional career in the Agency and its predecessor bodies. She is recognised as one of the leading experts in the field of medicines safety, playing a central role in the Agency’s work. I am delighted that she has agreed to act as interim chief executive of the Agency for the coming months.”


© 2022 Regulatory Affairs Professionals Society.

Tags: Brexit, Hudson, MHRA, Raine

Discover more of what matters to you

No taxonomy
No data found